Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia
- PMID: 25865094
- DOI: 10.1586/14787210.2015.1032254
Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) constitutes an increasing problem worldwide. CRAB bacteremia is associated with a high fatality rate and its optimal treatment has not been established. Early institution of appropriate therapy is shown to improve survival of patients with CRAB bloodstream infection. Regrettably, treatment options are limited. Little information exists about the efficacy of sulbactam for the treatment of CRAB bacteremia. Colistin and tigecycline possess good in vitro activity and represent in many cases the only therapeutic options although clinical data are scarce. The need for a loading dose of colistin has been recently demonstrated to rapidly achieve therapeutic levels. The use of combination therapy is also a matter of debate but current evidence do not support its routine use.
Keywords: Acinetobacter baumannii; bacteremia; carbapenem-resistant; colistin; polymyxin; tigecycline; treatment.
Similar articles
-
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172. J Int Med Res. 2013. PMID: 24265334
-
Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.J Microbiol Immunol Infect. 2016 Dec;49(6):934-940. doi: 10.1016/j.jmii.2014.10.006. Epub 2014 Nov 11. J Microbiol Immunol Infect. 2016. PMID: 25553994
-
Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.Pharmacotherapy. 2007 Nov;27(11):1506-11. doi: 10.1592/phco.27.11.1506. Pharmacotherapy. 2007. PMID: 17963460
-
Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.Expert Rev Anti Infect Ther. 2013 Apr;11(4):383-93. doi: 10.1586/eri.13.14. Expert Rev Anti Infect Ther. 2013. PMID: 23566148 Review.
-
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii.Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39081869 Free PMC article. Review.
Cited by
-
Carbapenem-resistant Gram-negative bacteria (CR-GNB) in ICUs: resistance genes, therapeutics, and prevention - a comprehensive review.Front Public Health. 2024 Mar 27;12:1376513. doi: 10.3389/fpubh.2024.1376513. eCollection 2024. Front Public Health. 2024. PMID: 38601497 Free PMC article. Review.
-
High mortality in an outbreak of multidrug resistant Acinetobacter baumannii infection introduced to an oncological hospital by a patient transferred from a general hospital.PLoS One. 2020 Jul 23;15(7):e0234684. doi: 10.1371/journal.pone.0234684. eCollection 2020. PLoS One. 2020. PMID: 32702006 Free PMC article.
-
Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.Infect Drug Resist. 2018 Aug 21;11:1249-1260. doi: 10.2147/IDR.S166750. eCollection 2018. Infect Drug Resist. 2018. PMID: 30174448 Free PMC article. Review.
-
Determinants of Mortality in Patients with Nosocomial Acinetobacter baumannii Bacteremia in Southwest China: A Five-Year Case-Control Study.Can J Infect Dis Med Microbiol. 2018 Jun 3;2018:3150965. doi: 10.1155/2018/3150965. eCollection 2018. Can J Infect Dis Med Microbiol. 2018. PMID: 29973964 Free PMC article.
-
Efficacies of Colistin-Carbapenem versus Colistin-Tigecycline in Critically Ill Patients with CR-GNB-Associated Pneumonia: A Multicenter Observational Study.Antibiotics (Basel). 2021 Sep 7;10(9):1081. doi: 10.3390/antibiotics10091081. Antibiotics (Basel). 2021. PMID: 34572663 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
